A new dawn for eosinophils in the tumour microenvironment

[1]  S. Ackerman,et al.  Contributions of Eosinophils to Human Health and Disease. , 2020, Annual review of pathology.

[2]  S. Qin,et al.  CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils , 2019, International journal of cancer.

[3]  P. Sestili,et al.  IL-33 Promotes CD11b/CD18-Mediated Adhesion of Eosinophils to Cancer Cells and Synapse-Polarized Degranulation Leading to Tumor Cell Killing , 2019, Cancers.

[4]  S. Loi,et al.  Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade , 2019, Clinical Cancer Research.

[5]  D. von Bubnoff,et al.  Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone , 2019, Cancer Immunology, Immunotherapy.

[6]  Y. Takeda,et al.  The postoperative peak number of leukocytes after hepatectomy is a significant prognostic factor for cholangiocarcinoma. , 2019, Molecular and clinical oncology.

[7]  G. Dranoff,et al.  GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. , 2019, Immunity.

[8]  V. Paradis,et al.  Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth , 2019, Nature Immunology.

[9]  J. Elisseeff,et al.  A biologic scaffold–associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy , 2019, Science Translational Medicine.

[10]  James J. Lee,et al.  Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer , 2019, Cancer Immunology Research.

[11]  D. Weiner,et al.  IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment , 2018, Oncoimmunology.

[12]  V. Bours,et al.  Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment , 2018, Oncotarget.

[13]  I. Donev,et al.  Quantitative Analysis of Tumor-associated Tissue Eosinophilia in Recurring Bladder Cancer , 2018, Cureus.

[14]  M. Fay,et al.  Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome. , 2018, The journal of allergy and clinical immunology. In practice.

[15]  W. Leonard,et al.  Biology and regulation of IL-2: from molecular mechanisms to human therapy , 2018, Nature Reviews Immunology.

[16]  Artem Barski,et al.  Reuse of public, genome‐wide, murine eosinophil expression data for hypotheses development , 2018, Journal of leukocyte biology.

[17]  A. Engert,et al.  Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition , 2018, British journal of haematology.

[18]  G. Marone,et al.  Eosinophils: The unsung heroes in cancer? , 2018, Oncoimmunology.

[19]  C. Loquai,et al.  Long-term survival with modern therapeutic agents against metastatic melanoma—vemurafenib and ipilimumab in a daily life setting , 2018, Medical Oncology.

[20]  Ash A. Alizadeh,et al.  Profiling Tumor Infiltrating Immune Cells with CIBERSORT. , 2018, Methods in molecular biology.

[21]  Wen-Jie Zhou,et al.  TSLP promotes angiogenesis of human umbilical vein endothelial cells by strengthening the crosstalk between cervical cancer cells and eosinophils. , 2017, Oncology letters.

[22]  J. Fahrenholz,et al.  Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. , 2017, The journal of allergy and clinical immunology. In practice.

[23]  P. Weller,et al.  Functions of tissue-resident eosinophils , 2017, Nature Reviews Immunology.

[24]  P. Fulkerson.  Transcription Factors in Eosinophil Development and As Therapeutic Targets , 2017, Front. Med..

[25]  F. Mattei,et al.  IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils , 2017, Oncoimmunology.

[26]  G. Garlet,et al.  Relevance of CCL3/CCR5 axis in oral carcinogenesis , 2017, Oncotarget.

[27]  V. Ponomarev,et al.  Inflammatory peroxidases promote breast cancer progression in mice via regulation of the tumour microenvironment. , 2017, International journal of oncology.

[28]  L. Heinzerling,et al.  Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. , 2017, Immunotherapy.

[29]  A. Munitz,et al.  Emerging Roles for Eosinophils in the Tumor Microenvironment. , 2016, Trends in cancer.

[30]  F. Liew,et al.  Interleukin-33 in health and disease , 2016, Nature Reviews Immunology.

[31]  M. Walsh,et al.  Eosinophil peroxidase activates cells by HER2 receptor engagement and β1-integrin clustering with downstream MAPK cell signaling , 2016, Clinical immunology.

[32]  M. Thiry,et al.  Lung-resident eosinophils represent a distinct regulatory eosinophil subset. , 2016, The Journal of clinical investigation.

[33]  D. Xue,et al.  HMGB1 promotes cellular chemokine synthesis and potentiates mesenchymal stromal cell migration via Rap1 activation. , 2016, Molecular medicine reports.

[34]  P. Ascierto,et al.  Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma , 2016, Cancer Immunology, Immunotherapy.

[35]  C. Berking,et al.  Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.

[36]  Yijun Tian,et al.  CCL11‐induced eosinophils inhibit the formation of blood vessels and cause tumor necrosis , 2016, Genes to cells : devoted to molecular & cellular mechanisms.

[37]  B. Lu,et al.  Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy , 2016, Journal of Molecular Medicine.

[38]  J. Cerhan,et al.  Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women’s Health Study , 2016, Modern Pathology.

[39]  D. Schadendorf,et al.  Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab , 2016, Clinical Cancer Research.

[40]  G. Kim,et al.  Eosinophils in Colorectal Neoplasms Associated with Expression of CCL11 and CCL24 , 2015, Journal of pathology and translational medicine.

[41]  M. Roussel,et al.  TNF Counterbalances the Emergence of M2 Tumor Macrophages. , 2015, Cell reports.

[42]  J. Utikal,et al.  Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab , 2015, Clinical Cancer Research.

[43]  J. Mei,et al.  The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell. , 2015, Cancer letters.

[44]  A. Dendooven,et al.  IL-18 Is Involved in Eosinophil-Mediated Tumoricidal Activity against a Colon Carcinoma Cell Line by Upregulating LFA-1 and ICAM-1 , 2015, The Journal of Immunology.

[45]  G. Hämmerling,et al.  Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells , 2015, Nature Immunology.

[46]  B. Fingleton,et al.  Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. , 2015, Cancer research.

[47]  K. Dyer,et al.  Physiologic Concentrations of HMGB1 Have No Impact on Cytokine-Mediated Eosinophil Survival or Chemotaxis in Response to Eotaxin-2 (CCL24) , 2015, PloS one.

[48]  H. Vestergaard,et al.  Association of the blood eosinophil count with hematological malignancies and mortality , 2015, American journal of hematology.

[49]  N. Rakesh,et al.  Tumour associated tissue eosinophilia as a predictor of locoregional recurrence in oral squamous cell carcinoma , 2015, Journal of clinical and experimental dentistry.

[50]  G. Dranoff,et al.  A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy , 1997, Cancer Immunology, Immunotherapy.

[51]  R. Locksley,et al.  Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. , 2014, Blood.

[52]  R. Melo,et al.  Unraveling the complexity of lipid body organelles in human eosinophils , 2014, Journal of leukocyte biology.

[53]  Rachel M. Webster.  The immune checkpoint inhibitors: where are we now? , 2014, Nature Reviews Drug Discovery.

[54]  H. Hirai,et al.  CCR1-mediated accumulation of myeloid cells in the liver microenvironment promoting mouse colon cancer metastasis , 2014, Clinical & Experimental Metastasis.

[55]  P. Kantoff,et al.  A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T , 2014, Cancer Immunology Research.

[56]  S. Rosenberg.  IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.

[57]  A. Munitz,et al.  Interleukin‐33 requires CMRF35‐like molecule‐1 expression for induction of myeloid cell activation , 2014, Allergy.

[58]  Hongzheng Ren,et al.  Clinical Impact of Tumor-Infiltrating Inflammatory Cells in Primary Small Cell Esophageal Carcinoma , 2014, International journal of molecular sciences.

[59]  Jun Li,et al.  Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression. , 2014, Oncology reports.

[60]  C. Berek,et al.  Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. , 2014, Immunity.

[61]  Megha Jain,et al.  Assessment of Tissue Eosinophilia as a Prognosticator in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma—An Image Analysis Study , 2014, Pathology research international.

[62]  M. Rothenberg,et al.  Eosinophils and Cancer , 2014, Cancer Immunology Research.

[63]  H. Vestergaard,et al.  Eosinophilia in routine blood samples as a biomarker for solid tumor development – A study based on The Copenhagen Primary Care Differential Count (CopDiff) Database , 2013, Acta oncologica.

[64]  J. Gilbert,et al.  Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. , 2013, Cancer research.

[65]  Lianfeng Zhang,et al.  Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. , 2013, Cancer letters.

[66]  James J. Lee,et al.  Homologous recombination into the eosinophil peroxidase locus generates a strain of mice expressing Cre recombinase exclusively in eosinophils , 2013, Journal of leukocyte biology.

[67]  A. Dvorak,et al.  Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. , 2013, Blood.

[68]  K. Dyer,et al.  Eosinophils: changing perspectives in health and disease , 2012, Nature Reviews Immunology.

[69]  Takahiro Matsumoto,et al.  Eosinophils Promote Epithelial to Mesenchymal Transition of Bronchial Epithelial Cells , 2013, PloS one.

[70]  F. Vizoso,et al.  Relationship between the Inflammatory Molecular Profile of Breast Carcinomas and Distant Metastasis Development , 2012, PloS one.

[71]  James J. Lee,et al.  Human versus mouse eosinophils: "that which we call an eosinophil, by any other name would stain as red". , 2012, The Journal of allergy and clinical immunology.

[72]  M. Capron,et al.  Involvement of eosinophils in the anti-tumor response , 2012, Cancer Immunology, Immunotherapy.

[73]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[74]  K. Tsuneyama,et al.  Identification of Innate IL-5–Producing Cells and Their Role in Lung Eosinophil Regulation and Antitumor Immunity , 2012, The Journal of Immunology.

[75]  P. Bertics,et al.  Human eosinophils express RAGE, produce RAGE ligands, exhibit PKC-delta phosphorylation and enhanced viability in response to the RAGE ligand, S100B. , 2011, International immunology.

[76]  M. Walsh,et al.  Eosinophil peroxidase signals via epidermal growth factor-2 to induce cell proliferation. , 2011, American journal of respiratory cell and molecular biology.

[77]  K. Leslie,et al.  Immunodetection of occult eosinophils in lung tissue biopsies may help predict survival in acute lung injury , 2011, Respiratory research.

[78]  P. Bertics,et al.  GM-CSF Production by Glioblastoma Cells Has a Functional Role in Eosinophil Survival, Activation, and Growth Factor Production for Enhanced Tumor Cell Proliferation , 2011, The Journal of Immunology.

[79]  D. Dombrowicz,et al.  Human Eosinophils Exert TNF-α and Granzyme A-Mediated Tumoricidal Activity toward Colon Carcinoma Cells , 2010, The Journal of Immunology.

[80]  B. Fingleton,et al.  Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. , 2010, American journal of respiratory and critical care medicine.

[81]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[82]  M. Antoni,et al.  Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study. , 2010, Journal of pain and symptom management.

[83]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[84]  James J. Lee,et al.  Eosinophils in health and disease: the LIAR hypothesis , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[85]  L. Coussens,et al.  Lymphocytes in cancer development: polarization towards pro-tumor immunity. , 2010, Cytokine & growth factor reviews.

[86]  I. McInnes,et al.  Disease-associated functions of IL-33: the new kid in the IL-1 family , 2010, Nature Reviews Immunology.

[87]  J. Kelley,et al.  A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer , 2010, Cancer Immunology, Immunotherapy.

[88]  T. Lombardi,et al.  Eosinophils and Oral Squamous Cell Carcinoma: A Short Review , 2009, Journal of oncology.

[89]  G. Cheng,et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.

[90]  Jeffrey R. Marks,et al.  Role of Eotaxin-1 Signaling in Ovarian Cancer , 2009, Clinical Cancer Research.

[91]  P. Tagliaferri,et al.  Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine , 2009, Cancer biology & therapy.

[92]  C. Dahinden,et al.  Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. , 2009, Blood.

[93]  D. Meyerholz,et al.  Comparison of Histochemical Methods for Murine Eosinophil Detection in an RSV Vaccine-enhanced Inflammation Model , 2009, Toxicologic pathology.

[94]  P. Weller,et al.  Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially , 2008, Journal of leukocyte biology.

[95]  M. Gore,et al.  Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[96]  H. Rosenberg,et al.  RNase A ribonucleases and host defense: an evolving story , 2008, Journal of leukocyte biology.

[97]  H. Rosenberg,et al.  Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2–MyD88 signal pathway in dendritic cells and enhances Th2 immune responses , 2008, The Journal of experimental medicine.

[98]  G. Ashton,et al.  Eotaxin-2 and Colorectal Cancer: A Potential Target for Immune Therapy , 2007, Clinical Cancer Research.

[99]  C. Wennerås,et al.  House dust mite allergen activates human eosinophils via formyl peptide receptor and formyl peptide receptor‐like 1 , 2007, European journal of immunology.

[100]  C. Parish,et al.  Eotaxin Selectively Binds Heparin , 2007, Journal of Biological Chemistry.

[101]  Marc E. Rothenberg,et al.  Regulation of Carcinogenesis by IL-5 and CCL11: A Potential Role for Eosinophils in Tumor Immune Surveillance1 , 2007, The Journal of Immunology.

[102]  M. Lotze,et al.  Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. , 2007, Journal of immunotherapy.

[103]  James J. Lee,et al.  Pivotal Advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response , 2006, Journal of leukocyte biology.

[104]  Takashi Suzuki,et al.  Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma. , 2006, Anticancer research.

[105]  M. Rothenberg,et al.  The eosinophil. , 2006, Annual review of immunology.

[106]  H. Ljunggren,et al.  Blockade of CTLA‐4 Promotes Airway Inflammation in Naive Mice Exposed to Aerosolized Allergen but Fails to Prevent Inhalation Tolerance , 2005, Scandinavian journal of immunology.

[107]  N. Lee,et al.  Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function? , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[108]  C. Wennerås,et al.  Human eosinophils selectively recognize and become activated by bacteria belonging to different taxonomic groups. , 2005, Microbes and infection.

[109]  L. Mastracci,et al.  Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. , 2005, Neoplasia.

[110]  D. Ribatti,et al.  Human peripheral blood eosinophils induce angiogenesis. , 2005, The international journal of biochemistry & cell biology.

[111]  S. Wiseman,et al.  Tissue eosinophilia: a morphologic marker for assessing stromal invasion in laryngeal squamous neoplasms , 2005, BMC clinical pathology.

[112]  O. Mandelboim,et al.  2B4 (CD244) Is Expressed and Functional on Human Eosinophils1 , 2005, The Journal of Immunology.

[113]  H. Huland,et al.  Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells , 2005, Journal of Cancer Research and Clinical Oncology.

[114]  A. Ghahary,et al.  Cutting Edge: Human Eosinophils Regulate T Cell Subset Selection through Indoleamine 2,3-Dioxygenase1 , 2004, The Journal of Immunology.

[115]  A. Tominaga,et al.  Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. , 2004, DNA and cell biology.

[116]  P. Foster,et al.  Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13 production and airway eosinophilia and hyperreactivity. , 2003, The Journal of allergy and clinical immunology.

[117]  C. Howland,et al.  Activated eosinophils upregulate the metastasis suppressor molecule E-cadherin on prostate tumor cells. , 2003, Cellular and molecular biology.

[118]  G. Landman,et al.  Eotaxin expression in oral squamous cell carcinomas with and without tumour associated tissue eosinophilia. , 2003, Oral diseases.

[119]  R. Dummer,et al.  Interleukin‐2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome , 2003 .

[120]  P. Foster,et al.  Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells , 2003, The Journal of experimental medicine.

[121]  P. Foster,et al.  Chemokines in asthma: cooperative interaction between chemokines and IL-13. , 2003, The Journal of allergy and clinical immunology.

[122]  G. Dunston,et al.  Activated eosinophils infiltrate MCF-7 breast multicellular tumor spheroids. , 2003, Anticancer research.

[123]  M. Rothenberg,et al.  Receptor internalization is required for eotaxin-induced responses in human eosinophils. , 2003, The Journal of allergy and clinical immunology.

[124]  G. Landman,et al.  Tumour‐associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas , 2002, Histopathology.

[125]  J. Brooks,et al.  Eosinophils as a Marker for Invasion in Cervical Squamous Neoplastic Lesions , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[126]  P. Foster,et al.  IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. , 2001, The Journal of allergy and clinical immunology.

[127]  S. Hazen,et al.  Eosinophils Are a Major Source of Nitric Oxide-Derived Oxidants in Severe Asthma: Characterization of Pathways Available to Eosinophils for Generating Reactive Nitrogen Species4 , 2001, The Journal of Immunology.

[128]  J. Erjefält,et al.  Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease , 2001, Thorax.

[129]  S. Hazen,et al.  Eosinophil Peroxidase Oxidation of Thiocyanate , 2001, The Journal of Biological Chemistry.

[130]  James J. Lee,et al.  Identification of a new murine eosinophil major basic protein (mMBP) gene: cloning and characterization of mMBP‐2 , 2000 .

[131]  M. Fernández-Aceñero,et al.  Prognostic influence of tumor‐associated eosinophilic infiltrate in colorectal carcinoma , 2000, Cancer.

[132]  V. Diehl,et al.  Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. , 2000, Blood.

[133]  C. Bertrand,et al.  CCR3 blockade as a new therapy for asthma , 2000, Expert opinion on investigational drugs.

[134]  H. Stein,et al.  Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. , 1999, Blood.

[135]  D. Wong,et al.  Eosinophil ablation and tumor development. , 1999, Oral oncology.

[136]  T. Nishi,et al.  A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. , 1999, Journal of immunology.

[137]  E. Jaffe,et al.  Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. , 1999, Blood.

[138]  D. Loegering,et al.  Cytotoxic Properties of Eosinophil Granule Major Basic Protein for Tumor Cells , 1999, International Archives of Allergy and Immunology.

[139]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[140]  D. Hoskin,et al.  Adhesion of tumoricidal eosinophils to MCA-38 colon adenocarcinoma cells involves protein tyrosine kinase activation and is diminished by elevated cyclic AMP in the effector cell. , 1998, International journal of oncology.

[141]  T. Suda,et al.  Models of lineage switching in hematopoietic development: a new myeloid-committed eosinophil cell line (YJ) demonstrates trilineage potential , 1998, Leukemia.

[142]  M. Baggiolini,et al.  Eotaxin-2, a Novel CC Chemokine that Is Selective for the Chemokine Receptor CCR3, and Acts Like Eotaxin on Human Eosinophil and Basophil Leukocytes , 1997, The Journal of experimental medicine.

[143]  M. Saleh.  The role of tumour-derived mIL-4 on rat C6 glioma regression. , 1997, International journal of oncology.

[144]  R. Gentz,et al.  Molecular and Functional Characterization of  Two Novel Human C-C Chemokines as Inhibitors of  Two Distinct Classes of Myeloid Progenitors , 1997, The Journal of experimental medicine.

[145]  C. V. D. van de Velde,et al.  Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG). , 1996, British Journal of Cancer.

[146]  A. Zwinderman,et al.  Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. , 1996, Human pathology.

[147]  C. Mackay,et al.  Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils , 1996, The Journal of experimental medicine.

[148]  J. Demartino,et al.  Cloning, expression, and characterization of the human eosinophil eotaxin receptor , 1996, The Journal of experimental medicine.

[149]  F. Graham,et al.  An adenoviral vector expressing interleukin-4 modulates tumorigenicity and induces regression in a murine breast-cancer model. , 1995, International Journal of Oncology.

[150]  T. Williams,et al.  Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo , 1995, The Journal of experimental medicine.

[151]  P. Leder,et al.  Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[152]  R. Fisher,et al.  Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[153]  C. Combadière,et al.  Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor (*) , 1995, The Journal of Biological Chemistry.

[154]  H. Seigler,et al.  Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. , 1994, Cellular immunology.

[155]  P. Bradley,et al.  Tumor-associated tissue eosinophilia and long-term prognosis for carcinoma of the larynx. , 1994, American journal of surgery.

[156]  S. Russell,et al.  Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[157]  M. Colombo,et al.  In vitro anti‐tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 , 1993, International journal of cancer.

[158]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[159]  L. Koenderman,et al.  Eosinophil migration in atopic dermatitis. I: Increased migratory responses to N-formyl-methionyl-leucyl-phenylalanine, neutrophil-activating factor, platelet-activating factor, and platelet factor 4. , 1993, The Journal of investigative dermatology.

[160]  B. Glimelius,et al.  Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis , 1993, Hematological oncology.

[161]  D. Jones.  The eosinophil. , 1993, Journal of comparative pathology.

[162]  P. Leder,et al.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.

[163]  C. Sanderson.  Interleukin-5, Eosinophils, and Disease , 1992 .

[164]  G. Gleich,et al.  Cytotoxicity of human eosinophil granule major basic protein to human nasal sinus mucosa in vitro. , 1990, The Journal of allergy and clinical immunology.

[165]  N. Yamaguchi,et al.  Distribution of IL-5 receptor-positive B cells. Expression of IL-5 receptor on Ly-1(CD5)+ B cells. , 1990, Journal of immunology.

[166]  R. L. Barker,et al.  In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. , 1990, Journal of immunology.

[167]  W. Owen,et al.  IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. , 1989, Journal of immunology.

[168]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[169]  R. Graziano,et al.  Fc gamma R-mediated killing by eosinophils. , 1989, Journal of immunology.

[170]  K. Grabstein,et al.  Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4) , 1987, The Journal of experimental medicine.

[171]  I. Olsson,et al.  Localization of eosinophil cationic protein, major basic protein, and eosinophil peroxidase in human eosinophils by immunoelectron microscopic technique. , 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[172]  T. Fujimura,et al.  Malignant tumor and eosinophils: I. Prognostic significance in gastric cancer , 1986, Cancer.

[173]  D. Loegering,et al.  Eosinophil- and eosinophil granule-mediated pneumocyte injury. , 1985, The Journal of allergy and clinical immunology.

[174]  D. Lowe,et al.  Tumour-associated eosinophilia in the bladder. , 1984, Journal of clinical pathology.

[175]  M. Brennan,et al.  Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer , 2006, Cancer.

[176]  T. P. Pretlow,et al.  Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. , 1983, Cancer research.

[177]  F. Finkelman,et al.  Induction of a B-lymphocyte receptor for a T cell-replacing factor by the crosslinking of surface IgD. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[178]  D. Loegering,et al.  Localization of the guinea pig eosinophil major basic protein to the core of the granule , 1978, The Journal of cell biology.